Stock Events

Stock Events

Immupharma 

€0.05
0
+€0+0% Wednesday 07:31

Statistics

Day High
0.05
Day Low
0.05
52W High
0.19
52W Low
0.01
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MayExpected
Q2 2021
Next
-0.02
0.32
0.65
0.98
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 25I.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a biopharmaceutical company that competes in the development of treatments for autoimmune diseases, a key area of focus for Immupharma.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie operates in the same biopharmaceutical space, focusing on immunology and chronic diseases, directly competing with Immupharma's product pipeline.
AMGEN
AMGN
Mkt Cap178B
Amgen is a competitor due to its extensive work in biologics for treating autoimmune diseases, overlapping with Immupharma's research and development efforts.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb competes in the immunology and oncology sectors, areas where Immupharma is striving to make advancements.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG, through its pharmaceuticals division, develops treatments for various diseases, including autoimmune diseases, competing with Immupharma's research focus.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a global pharmaceutical company with a broad product line that includes treatments for autoimmune diseases, making it a competitor to Immupharma.
Novartis
NVS
Mkt Cap279.67B
Novartis focuses on innovative medicines, including those for autoimmune diseases, directly competing with Immupharma's development pipeline.
Biogen
BIIB
Mkt Cap27.62B
Biogen specializes in neurology and autoimmune diseases, areas that overlap with Immupharma's therapeutic focus, making it a direct competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is involved in the discovery and development of pharmaceutical products for treating autoimmune diseases, competing with Immupharma.
Sanofi
SNY
Mkt Cap110.4B
Sanofi operates in the pharmaceutical sector focusing on treatments for autoimmune diseases among others, positioning it as a competitor to Immupharma.

About

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Show more...
CEO
Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A.
Employees
6
Country
United Kingdom
ISIN
GB0033711010

Listings

STU
DE
25I.STU
MU
DE
25I.MU
LSE
GB
IMM.LSE
F
DE
25I.F

0 Comments

Share your thoughts

FAQ

What is Immupharma stock price today?▼
The current price of 25I.STU is €0.05 EUR — it has increased by +0% in the past 24 hours. Watch Immupharma stock price performance more closely on the chart.
What is Immupharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immupharma stocks are traded under the ticker 25I.STU.
Is Immupharma stock price growing?▼
25I.STU stock has risen by +0% compared to the previous week, the month change is a -0% fall, over the last year Immupharma has showed a +47.54% increase.
When is the next Immupharma earnings date?▼
Immupharma is going to release the next earnings report on May 26, 2026.
What were Immupharma earnings last quarter?▼
25I.STU earnings for the last quarter are -0.02 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Immupharma have?▼
As of May 06, 2026, the company has 6 employees.
In which sector is Immupharma located?▼
Immupharma operates in the Health & Wellness sector.
When did Immupharma complete a stock split?▼
Immupharma has not had any recent stock splits.
Where is Immupharma headquartered?▼
Immupharma is headquartered in London, United Kingdom.